Liver-specific constructs, factor VIII expression cassettes and methods of use thereof

Patent metadata

Field	Value
Publication number	US-10143760-B2
Application number	US-201615209363-A
Country	US
Kind code	B2
Filing date	Jul 13, 2016
Priority date	Oct 28, 2015
Publication date	Dec 4, 2018
Grant date	Dec 4, 2018

Abstract

Described herein are constructs used for liver-specific expression of a transgene.

First claim

What is claimed is:

1. A polynucleotide expression construct comprising SEQ ID NO:34.

2. The polynucleotide expression construct of claim 1 , wherein the polynucleotide expression construct is flanked by a 5′ inverted terminal repeat (ITR) and a 3′ ITR.

3. A vector comprising the polynucleotide expression construct of claim 1 .

4. The vector of claim 3 , wherein the vector is a viral or a non-viral vector.

5. The vector of claim 4 , wherein the vector is an adeno-associated virus (AAV) vector comprising the polynucleotide expression construct, wherein the polynucleotide expression construct is flanked by 5′ and 3′ AAV inverted terminal repeat sequences (ITRs).

6. The vector of claim 5 , wherein the ITRs are AAV2 ITRs.

7. The vector of claim 6 , wherein the vector further comprises an AAV serotype 6 (AAV6) capsid.

8. A pharmaceutical composition comprising the vector of claim 7 and a pharmaceutically acceptable carrier.

9. A kit comprising the AAV vector of claim 7 .

10. A polynucleotide expression construct comprising SEQ ID NO:37.

11. The polynucleotide expression construct of claim 10 , wherein the polynucleotide expression construct is flanked by a 5′ ITR and a 3′ ITR.

12. A vector comprising the polynucleotide expression construct of claim 10 .

13. The vector of claim 12 , wherein the vector is a viral or a non-viral vector.

14. The vector of claim 13 , wherein the vector is an adeno-associated virus (AAV) vector comprising the polynucleotide expression construct, wherein the polynucleotide expression construct is flanked by a 5′ and a 3′ ITR.

15. The vector of claim 14 , wherein the ITRs are AAV2 ITRs.

16. The vector of claim 15 , wherein the vector further comprises an AAV serotype 6 (AAV6) capsid.

17. A pharmaceutical composition comprising the vector of claim 16 , and a pharmaceutically acceptable carrier.

18. A kit comprising the vector of claim 16 .

19. A polynucleotide expression construct comprising a liver-specific enhancer sequence, a promoter sequence, an intron sequence, and a transgene, wherein the intron sequence comprises the sequence of SEQ ID NO: 15, SEQ ID NO:16, SEQ ID NO:17, or nucleotides 340-432 of SEQ ID NO:37.

20. The polynucleotide expression construct of claim 19 , wherein the intron comprises nucleotides 340-432 of SEQ ID NO: 37.

21. The polynucleotide expression construct of claim 19 , wherein:
a). the enhancer sequence comprises a wild-type or mutated SerpinA1 enhancer; or
b). the promoter sequence comprises a wild-type or mutated the transthyretin (TTR) promoter; or
c). the enhancer sequence comprises a wild-type or mutated SerpinA1 enhancer and the promoter sequence comprises a wild-type or mutated the transthyretin (TTR) promoter.

22. The polynucleotide expression construct of claim 21 , further comprising:
a.) at least one spacer sequence comprising an insulator sequence;
b.) a polyadenylation signal; or
c.) at least one spacer sequence comprising an insulator sequence and a polyadenylation signal.

23. The polynucleotide expression construct of claim 19 , further comprising at least one spacer sequence comprising an insulator sequence selected from the group consisting of SEQ ID NO: 28 and SEQ ID NO:30.

24. The polynucleotide expression construct of claim 23 , further comprising an enhancer comprising SEQ ID NO:36.

25. The polynucleotide expression construct of claim 19 , wherein the transgene encodes a protein lacking or deficient in a hemophilia or a lysosomal storage disease.

26. The polynucleotide expression construct of claim 25 , wherein the transgene encodes a human B-domain deleted factor VIII protein (BDD FVIII).

27. The polynucleotide expression construct of claim 25 , wherein the transgene further encodes one or more nucleases.

28. An adeno-associated virus (AAV) vector comprising the polynucleotide expression construct of claim 19 , wherein the polynucleotide expression construct is flanked by 5′ and 3′ AAV inverted terminal repeat sequences (ITRs).

29. The AAV vector of claim 28 , wherein the intron comprises nucleotides 340-432 of SEQ ID NO:37.

30. The AAV vector of claim 29 , the polynucleotide comprising an insulator comprising the sequence of SEQ ID NO:28 (Ins1) on the 5′ terminus after the 5′ ITR and an insulator comprising the sequence of SEQ ID NO:30 on the 3′ terminus before the 3′ ITR.

31. The AAV vector of claim 30 , wherein the ITRs are from AAV2.

32. The AAV vector of claim 31 , wherein the vector comprises an AAV6 capsid.

33. A pharmaceutical composition comprising the AAV vector of claim 32 , and a pharmaceutically acceptable carrier.

34. A kit comprising the polynucleotide expression construct according to claim 19 .

Assignees

• Sangamo Therapeutics Inc

Inventors

• Riley Brigit E
• Lee Gary K

Classifications

• C12N2830/60

  from viruses · CPC title

• C12N2830/42

  being an intron or intervening sequence for splicing and/or stability of RNA · CPC title

• C12N2830/008

  cell type or tissue specific enhancer/promoter combination · CPC title

• C12N2750/14145

  Special targeting system for viral vectors · CPC title

• C12N2750/14143

  viral genome or elements thereof as genetic vector · CPC title